. Author manuscript; available in PMC: 2022 Sep 16.

Published in final edited form as: Clin Microbiol Infect. 2021 Apr 17;27(10):1448–1454. doi: 10.1016/j.cmi.2021.04.004

Table 3.

Base-case result of total cost, QALY, ICER and INMB

Treatment	Cost		QALY

EP fidaxomicin	$37 613	($35 795–$38 196)^b	11.65	(13.42–14.22)^b
Vancomycin	$39 178	($36 715–$39 951)^b	11.64	(13.40–14.19)^b
Fidaxomicin	$39 325	($37 113–$39 690)^b	11.94	(13.69–4.50)^b
Bezlotoxumab-vancomycin	$41 461	($39 079–$41 864)^b	11.77	(13.52–14.32)^b

Treatment	ICER (vs Vancomycin)		INMB (vs Vancomycin)^a

EP fidaxomicin	Dominant	(−$127 102 to −$16 844)^b	$3,248	($1817–$9230)^b
Fidaxomicin	$495	(−$1384 to $1957)^b	$44 308	($41 378–$49 478)^b
Bezlotoxumab-vancomycin	$17 746	($12 117–$23 360)^b	$17 011	($13 136–$21 164)^b

Treatment	ICER (vs EP fidaxomicin)		INMB (vs EP fidaxomicin)^a

Fidaxomicin	$6004	($4222–$6162)^b	$41 060	($36 493–$43 389)^b

At willingness-to-pay threshold of $150 000 per QALY.

Reported ranges are 80% uncertainty interval based on probabilistic sensitivity analysis.Abbreviations: EP, extended-pulsed; ICER, incremental cost-effectiveness ratio; INMB, incremental net monetary benefit; QALY, quality-adjusted life-year.